BioSpace News Archive

Pattern Bioscience, Inc. today announced that it was named the winner of the Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine (ADLM, formerly known as AACC).

Sera Prognostics Inc. today announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023, after the close of the market.

Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced the publication of a first-in-human study featuring the FreeClimb® 70 reperfusion system in the Interventional Neuroradiology Journal.

AnaptysBio, Inc. (Nasdaq: ANAB) today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

The Society for Vascular Surgery, the leading medical organization dedicated to advancing quality in vascular health care, has issued a response to a recent New York Times article detailing allegations of overuse of interventions to treat patients with peripheral vascular disease.

Solve GNE, a Los Angeles based non-profit organization, has raised over $2.5 million and negotiated sponsored research agreements with multiple leading medical researchers to help develop a cure for Hereditary Inclusion Body Myopathy.

Defender Pharmaceuticals, Inc., a privately held life sciences company based in St. Louis, announced that it had entered into an exclusive license agreement with the U.S. Army Medical Materiel Development Activity, a subordinate laboratory of the U.S. Army.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) today announced it will report its financial results from the second quarter ended June 30, 2023, after the financial markets close on Monday, August 7, 2023.

Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA) reported second quarter 2023 financial results and business highlights.